126 related articles for article (PubMed ID: 30317661)
1. CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.
Tsai HC; Chang AC; Tsai CH; Huang YL; Gan L; Chen CK; Liu SC; Huang TY; Fong YC; Tang CH
J Cell Physiol; 2019 Jun; 234(6):9297-9307. PubMed ID: 30317661
[TBL] [Abstract][Full Text] [Related]
2. Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2.
Xie ZY; Liu MS; Zhang C; Cai PC; Xiao ZH; Wang FF
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30120100
[No Abstract] [Full Text] [Related]
3. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
5. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
8. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d.
Tsai HC; Su HL; Huang CY; Fong YC; Hsu CJ; Tang CH
Oncotarget; 2014 Jun; 5(11):3800-12. PubMed ID: 25003330
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
10. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS
Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481
[TBL] [Abstract][Full Text] [Related]
12. SMAR1 attenuates the stemness of osteosarcoma cells via through suppressing ABCG2 transcriptional activity.
Xu H; Liu T; Li W; Yao Q
Environ Toxicol; 2021 Jun; 36(6):1090-1098. PubMed ID: 33543840
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
14. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
16. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
17. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
[TBL] [Abstract][Full Text] [Related]
18. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions.
Sasaki N; Ishiwata T; Hasegawa F; Michishita M; Kawai H; Matsuda Y; Arai T; Ishikawa N; Aida J; Takubo K; Toyoda M
Cancer Sci; 2018 Apr; 109(4):1135-1146. PubMed ID: 29444383
[TBL] [Abstract][Full Text] [Related]
19. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
Liu H; Song X; Hou J; Zhao Z; Chang J
DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
[TBL] [Abstract][Full Text] [Related]
20. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
Dai Y; Liu S; Zhang WQ; Yang YL; Hang P; Wang H; Cheng L; Hsu PC; Wang YC; Xu Z; Jablons DM; You L
Oncotarget; 2017 Jan; 8(3):4096-4109. PubMed ID: 27911857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
